PaxMedica Past Earnings Performance
Past criteria checks 0/6
PaxMedica's earnings have been declining at an average annual rate of -29.9%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually.
Key information
-29.9%
Earnings growth rate
0.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -1,525.1% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How PaxMedica makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -18 | 12 | 4 |
| 31 Dec 23 | 0 | -18 | 12 | 4 |
| 30 Sep 23 | 0 | -18 | 14 | 3 |
| 30 Jun 23 | 0 | -23 | 14 | 1 |
| 31 Mar 23 | 0 | -20 | 12 | 1 |
| 31 Dec 22 | 0 | -15 | 9 | 2 |
| 30 Sep 22 | 0 | -3 | 5 | 2 |
| 30 Jun 22 | 0 | 4 | 4 | 2 |
| 31 Mar 22 | 0 | -2 | 5 | 3 |
| 31 Dec 21 | 0 | -10 | 5 | 2 |
| 30 Sep 21 | 0 | -21 | 5 | 2 |
| 30 Jun 21 | 0 | -21 | 5 | 2 |
| 31 Mar 21 | 0 | -16 | 6 | 1 |
| 31 Dec 20 | 0 | -9 | 5 | 1 |
| 30 Jun 20 | 0 | -2 | 2 | 1 |
| 31 Mar 20 | 0 | -1 | 0 | 1 |
| 31 Dec 19 | 0 | -1 | 0 | 0 |
Quality Earnings: PXMD is currently unprofitable.
Growing Profit Margin: PXMD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PXMD is unprofitable, and losses have increased over the past 5 years at a rate of 29.9% per year.
Accelerating Growth: Unable to compare PXMD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PXMD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.9%).
Return on Equity
High ROE: PXMD has a negative Return on Equity (-1525.13%), as it is currently unprofitable.